Edward Allera

Healthcare attorney and co-chair of Buchanan Ingersoll & Rooney’s FDA group at Buchanan Ingersoll & Rooney
On the record
Represented by:
Recent Quotes
Sign up to view all
  • Generic-drug manufacturers, which source most of their active ingredients from China and India and are already enduring massive spending cuts amid the deflationary market, could be hit the hardest. Generic-drug manufacturers, which source most of their active ingredients from China and India and are already enduring massive spending cuts amid the deflationary market, could be hit the hardest.

    Changing suppliers for drug companies is very hard and takes a long time to get approved. In a competitive, deflationary industry where it is a race to the bottom, the impact could be significant.

    25 August 2020
Employment
Sign up to view all
  • Buchanan Ingersoll & Rooney
    Healthcare attorney and co-chair of Buchanan Ingersoll & Rooney’s FDA group